Background Patients with active cancer have an increased risk of venous thromboembolism,
which results in substantial morbidity, mortality, and health care expenditures. The Khorana …

Background Infection by the 2019 novel coronavirus (COVID-19) has been reportedly
associated with a high risk of thrombotic complications. So far information is scarce and rapidly …

Background Venous thromboembolism may be the earliest sign of cancer. Currently, there
is a great diversity in practices regarding screening for occult cancer in a person who has an …

Background Retrospective analyses suggest that pulmonary embolism is ruled out by a d-dimer
level of less than 1000 ng per milliliter in patients with a low clinical pretest probability (C…

Background— Long-term low-molecular-weight heparin (LMWH) is the current standard for
treatment of venous thromboembolism (VTE) in cancer patients. Whether treatment strategies …

Introduction Venous thromboembolism (VTE) has been observed as a frequent complication
in patients with severe novel coronavirus disease 2019 (COVID-19) infection requiring …

Oral factor Xa inhibitors are increasingly used for anticoagulation, but there is no approved
reversal agent. Prothrombin complex concentrate (PCC) for the management of Xa-inhibitor–…

Purpose: To update the American Society of Clinical Oncology (ASCO)/American Society of
Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in …

Stevens-Johnson (SJS) and Toxic Epidermal Necrolysis (TEN) are two uncommon
mucocutaneous diseases usually considered as severe drug reactions and are characterized by …

Venous thromboembolism (VTE) is a serious and often fatal medical condition with an
increasing incidence. The treatment of VTE is undergoing tremendous changes with the …